Christian Hackenberger on Tubulis: From academic startup to multibillion-dollar biotech acquisition
By
Laura Howes
1mo ago· 9 min readen
Summary
Christian Hackenberger, a chemist and founder of Tubulis, shares the story of how his academic startup grew into a multibillion-dollar acquisition. The article covers his journey from academic research in chemical biology to founding a biotech company focused on antibody-drug conjugates (ADCs), the challenges of bridging academia and industry, and what his Berlin-based lab is working on next.
Source
bskyChristian Hackenberger on Tubulis: From academic startup to multibillion-dollar biotech acquisitioncen.acs.orgKey quotes
· 3 pulledJust kidding. Of course it is phosphorus.
We didn't set out to build a company — we set out to solve a problem in chemistry that had real therapeutic potential.
The transition from academia to industry is not just about the science — it's about learning a completely different language and mindset.
Christian Hackenberger talks to C&EN about the story behind Tubulis and what his Berlin-based lab is working on next
You might also wanna read
Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal
The Daily Upside·12d ago
Alp Bio's AI platform predicts immune reactions to biologic drugs in early development
An interview with Christian Vahlensieck, co-founder of Alp Bio, a Swiss startup using an AI-powered platform combined with lab-grown human i
vist.ly·14d ago
Alp Bio's AI platform predicts immune reactions to biologic drugs earlier in development
An interview with Christian Vahlensieck, co-founder of Alp Bio, a Swiss startup using an AI-powered platform combined with lab-grown human i
vist.ly·12d ago
Dank KI-Boom: So viele Start-ups gegründet wie noch nie
tagesschau·1d ago
Aureka Opens Its Drug Discovery Model as AI Biotech Moves Toward Lab-Linked Systems
runtimewire.com·1d ago
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
STAT·1d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.